Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study

作者：Jackson Christopher G C A; Sharples Katrina; Thompson Paul I; O' Donnell Anne; Robinson Bridget Anne; Perez David J; Adams Jacqui; Isaacs Richard; Deva Sanjeev; Hinder Victoria A; Findlay Michael P^*

来源：BMC Cancer, 2014, 14(1): 737.

DOI：10.1186/1471-2407-14-737

• (6 in alphabetical order) bevacizumab
• Capecitabine
• Dose-intense
• Colorectal cancer

Background: Dose intense chemotherapy may improve efficacy with acceptable toxicity. A phase II study was conducted to determine the feasibility of a dose-intense two weekly schedule of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer (mCRC). %26lt;br%26gt;Methods: 49 patients with previously untreated mCRC were recruited. Nineteen received capecitabine (1750 mg/m(2) oral BD days 1-7) oxaliplatin (85 mg/m(2) i.v. day 1) and bevacizumab (5 mg/kg i.v. day 1) using a 14-day cycle (C1750). Following toxicity concerns capecitabine was reduced to 1500 mg/m(2) oral BD (C1500) and 30 further patients recruited. %26lt;br%26gt;Results: Over 80% of patients received at least 75% of planned chemotherapy doses over the first two cycles. At C1750 Grade 3 or higher toxicity occurred in 74% (95% CI 49% to 91%) and on C1500 in 70% (95% CI 51% to 85%). The median progression-free survival was 6.9 months (95% CI 4.7 to 8.7) for C1750 dose and 8.9 months (95% CI 4.1 to 12.4) for C1500. 3 treatment-related deaths occurred. %26lt;br%26gt;Conclusions: Dose intense capecitabine and oxaliplatin with bevacizumab does not show additional efficacy and has potentially significant toxicity. Its use outside of clinical trials is not recommended.

• 出版日期2014-10-2